Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

AstraZeneca Symbicort U.S. Filing Awaits Results of Formoterol Trials

  • News

Executive Summary

A U.S. NDA filing for AstraZeneca's combination asthma therapy Symbicort awaits completion of Phase III trials of the beta agonist (formoterol) component.

You may also be interested in...



Novartis Foradil Higher-Dose Phase IV Studies Slated For Completion By 2003

Novartis will study higher doses of Foradil (formoterol) as a postmarketing commitment associated with FDA's Feb. 16 approval of the asthma therapy.

Novartis Foradil Higher-Dose Phase IV Studies Slated For Completion By 2003

Novartis will study higher doses of Foradil (formoterol) as a postmarketing commitment associated with FDA's Feb. 16 approval of the asthma therapy.

AstraZeneca Anticoagulant NDA Delayed; Crestor v. Lipitor Data In March

AstraZeneca plans to submit an NDA for the oral direct thrombin inhibitor H376/95 in the second half of 2002.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS036593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By